PENGARUH PEMBERIAN ATORVASTATIN TERHADAP PERUBAHAN PROFIL LIPID DAN PETANDA INFLAMASI TNF-α PADA PASIEN DIABETES DENGAN DISLIPIDEMIA (Penelitian dilakukan di Poliklinik Ilmu Penyakit Dalam RSU Haji Surabaya)

WULAN PANDUWI MELASARI, 051515153010 (2017) PENGARUH PEMBERIAN ATORVASTATIN TERHADAP PERUBAHAN PROFIL LIPID DAN PETANDA INFLAMASI TNF-α PADA PASIEN DIABETES DENGAN DISLIPIDEMIA (Penelitian dilakukan di Poliklinik Ilmu Penyakit Dalam RSU Haji Surabaya). Thesis thesis, Universitas Airlangga.

[img]
Preview
Text (ABSTRAK)
ABSTRACT .pdf

Download (2MB) | Preview
[img] Text (FULLTEXT)
TFK 09-18 Mel p.pdf
Restricted to Registered users only until 9 March 2021.

Download (2MB) | Request a copy
Official URL: http://lib.unair.ac.id

Abstract

Background – Diabetics patients have 2 to 4 times increased risk of cardiovascular disease compared with non-diabetics. TNF-α is a proinflammatory cytokine that can be used to determine the risk of atherosclerosis complications triggered by inflammation in diabetes. Statins are a class of HMG CoA reductase inhibitors that inhibit cholesterol biosynthesis and have pleioropic effects that inhibit the release of inflammatory cytokines like TNF-α and stabilize atherosclerotic plaques. Objectives – This study aims to determine the effect of atorvastatin 20 mg/day for 30 days in reducing the lipid profile and TNF-α inflammatory markers in patients with diabetes dyslipidemia. Methods – Diabetes patient with dyslipidemia who included the inclusion criteria in this observational prospective cohorts studies treated with atorvastatin for 30 days (n = 19). The efficacy of statin therapy was measured by lipid profiles (LDL, TG, HDL, and total cholesterol) and TNF-α. Result – The results of the study showed that atorvastatin decreased 40.55% of LDL levels, 15.34% of TG levels, and 30.70% oftotal cholesterol levels which statistically significant (p<0.05). As for HDL, there is an increase of 6.06% but statistically nonsignificant (p>0.05). TNF-α levels increased by 11.30% which statistically non-significant (p> 0.05). Conclusion – The use of atorvastatin 20 mg for 30 days gave reduction in LDL, TG, and total cholesterol and increased in HDL. Atorvastatin doesn’t have a reducing effect on TNF-α. There was no correlation between lipid profile changes with TNF-α changes.

Item Type: Thesis (Thesis)
Additional Information: KKB KK-2 TFK.09/18 Mel p
Uncontrolled Keywords: Atorvastatin, lipid, TNF-α, diabetes, dyslipidemia
Subjects: R Medicine > RC Internal medicine > RC31-1245 Internal medicine
R Medicine > RS Pharmacy and materia medica
Divisions: 05. Fakultas Farmasi > Farmasi Klinis
Creators:
CreatorsNIM/NIDN
WULAN PANDUWI MELASARI, 051515153010UNSPECIFIED
Contributors:
ContributionNameNIDN/NIDK/NUP
ContributorSuharjono, Prof. Dr. , MS., AptUNSPECIFIED
ContributorWiwid Samsulhadi, dr. , Sp.PD, FINASIMUNSPECIFIED
ContributorNur Palestin A., S.Farm., M. Farm.Klin, AptUNSPECIFIED
Depositing User: sugiati
Date Deposited: 08 Mar 2018 20:56
Last Modified: 08 Mar 2018 20:56
URI: http://repository.unair.ac.id/id/eprint/70522
Sosial Share:

Actions (login required)

View Item View Item